Latest & greatest articles for copd exacerbations

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd exacerbations or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd exacerbations and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd exacerbations

121. Secular trends in nosocomial infections and mortality associated with noninvasive ventilation in patients with exacerbation of COPD and pulmonary edema. Full Text available with Trip Pro

the routine implementation of NIV and its effect on patients admitted to the intensive care unit (ICU) with acute exacerbation of chronic obstructive pulmonary disease (COPD) or severe cardiogenic pulmonary edema (CPE).Retrospective, observational cohort study using prospectively collected data from January 1, 1994, through December 31, 2001.A 26-bed medical intensive care unit (ICU) of a French university referral hospital.A cohort of 479 consecutive patients ventilated for acute exacerbation of COPD (...) Secular trends in nosocomial infections and mortality associated with noninvasive ventilation in patients with exacerbation of COPD and pulmonary edema. Randomized controlled trials have shown that the use of noninvasive ventilation (NIV) reduces the need for endotracheal intubation and invasive mechanical ventilation and reduces complication rates and mortality in selected groups of patients. But whether these benefits translate to a clinical setting is unclear.To evaluate longitudinally

2003 JAMA

122. Hospital at home for acute exacerbations of chronic obstructive pulmonary disease. (Abstract)

Hospital at home for acute exacerbations of chronic obstructive pulmonary disease. Hospital at home schemes are a recently adopted method of service delivery for the management of acute exacerbations of chronic obstructive pulmonary disease aimed at reducing demand for acute hospital in-patient beds and promoting a patient centered approach through admission avoidance. However, evidence in support of such a service is contradictory.To evaluate the efficacy of "hospital at home" compared (...) to hospital inpatient care in acute exacerbations of chronic obstructive pulmonary disease.The Cochrane Central Register of Controlled Trials; electronically available databases e.g. MEDLINE (1966-current), EMBASE (1980-current), PubMed, ClincalTrials, Science Citation Index and on-line individual respiratory journals; bibliographies of included trials were all searched and contact with authors was made to obtain studies. The most recent searches were carried out in August 2003.Only randomised controlled

2003 Cochrane

123. Cost effectiveness of ward based non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease: economic analysis of randomised controlled trial. Full Text available with Trip Pro

hospitals in the United Kingdom.The trial comprised 236 patients admitted to hospital with an acute exacerbation of chronic obstructive pulmonary disease and mild to moderate acidosis (pH 7.25-7.35) secondary to respiratory failure. The economic analysis compared the costs of treatment that these patients received after randomisation.Incremental cost per in-hospital death.24/118 died in the group receiving standard treatment and 12/118 in the group receiving non-invasive ventilation (P=0.05). Allocation (...) Cost effectiveness of ward based non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease: economic analysis of randomised controlled trial. To evaluate the cost effectiveness of standard treatment with and without the addition of ward based non-invasive ventilation in patients admitted to hospital with an acute exacerbation of chronic obstructive pulmonary disease.Incremental cost effectiveness analysis of a randomised controlled trial.Medical wards in 14

2003 BMJ Controlled trial quality: predicted high

124. Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from noninvasive positive-pressure ventilation: a systematic review of the literature

exacerbations. Authors' objectives To assess the effects of noninvasive positive-pressure ventilation (NPPV) in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD). Searching MEDLINE (from 1966 to December 2002), EMBASE (from January 1990 to June 2002) and the Cochrane Library were searched without any language restrictions; the search terms were given. Abstracts of the following meetings were handsearched from 1990 to 2002: the American Thoracic Society, the American College (...) Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from noninvasive positive-pressure ventilation: a systematic review of the literature Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from noninvasive positive-pressure ventilation: a systematic review of the literature Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from noninvasive positive-pressure ventilation: a systematic

2003 DARE.

125. Cost-effectiveness of ward based non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease: economic analysis of randomised controlled trial

Cost-effectiveness of ward based non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease: economic analysis of randomised controlled trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 NHS Economic Evaluation Database.

126. Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients

E, Vilagut G, Collvinent B, Rodriguez-Roisin R, Roca J. Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients. European Respiratory Journal 2003; 21(1): 58-67 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Aged; Cost-Benefit Analysis; Female; Follow-Up Studies; Home Care Services, Hospital-Based /economics; Hospitalization /economics; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive /therapy; Quality of Life; Time Factors (...) Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients Hernandez C, Casas A, Escarrabill J, Alonso J, Puig-Junoy J, Farrero E, Vilagut G, Collvinent B, Rodriguez-Roisin R, Roca J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each

2003 NHS Economic Evaluation Database.

127. Domiciliary non-invasive ventilation for recurrent acidotic exacerbations of COPD: an economic analysis

. Bibliographic details Tuggey J M, Plant P K, Elliott M W. Domiciliary non-invasive ventilation for recurrent acidotic exacerbations of COPD: an economic analysis. Thorax 2003; 58(10): 867-871 PubMedID Other publications of related interest Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet 2000;355:1931-5. Thys F, Roeseler J, Reynaert M, et al (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of domiciliary noninvasive ventilation (NIV) for the management of patients with recurrent admissions because of an acidotic exacerbation of chronic obstructive pulmonary disease (COPD). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients

2003 NHS Economic Evaluation Database.

128. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. Full Text available with Trip Pro

New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. The role of bacterial pathogens in acute exacerbations of chronic obstructive pulmonary disease is controversial. In older studies, the rates of isolation of bacterial pathogens from sputum were the same during acute exacerbations and during stable disease. However, these studies did not differentiate among strains within a bacterial species and therefore could not detect changes in strains over time. We (...) hypothesized that the acquisition of a new strain of a pathogenic bacterial species is associated with exacerbation of chronic obstructive pulmonary disease.We conducted a prospective study in which clinical information and sputum samples for culture were collected monthly and during exacerbations from 81 outpatients with chronic obstructive pulmonary disease. Molecular typing of sputum isolates of nonencapsulated Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae, and Pseudomonas

2002 NEJM

129. Heliox for treatment of exacerbations of chronic obstructive pulmonary disease. Full Text available with Trip Pro

Heliox for treatment of exacerbations of chronic obstructive pulmonary disease. Due to its low density properties, helium-oxygen mixtures have the potential to decrease the work of breathing and possibly avoid the need for intubation and mechanical ventilation in patients with respiratory failure.To determine the effect of the addition of helium/oxygen mixtures (heliox) to standard medical care during ventilated and nonventilated acute exacerbations of COPD.Randomized controlled trials were (...) identified from the Cochrane Airways Review Group asthma Register. Primary authors and experts were contacted. References from included and excluded studies, known reviews and texts were also searched.Studies were selected for inclusion if they compared treatment with heliox to placebo (oxygen or air) in randomized controlled trials in adults with an exacerbation of COPD.Data from all trials were combined using the Review Manager (version 4.1). We planned to perform: 1) random effects weighted mean

2002 Cochrane

130. Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review

benefit to patients with acute exacerbations of chronic obstructive pulmonary disease (COPD). The adverse effects of systemic steroid therapy were reviewed separately. Searching For the evaluation of effectiveness, MEDLINE was searched from 1966 to February 2002) using the MeSH terms 'steroids', 'obstructive lung disease', 'respiratory insufficiency', and the textword 'exacerbation'. The search was limited to clinical trials conducted in humans and published in the English language; publications (...) that included the subject heading 'asthma' were excluded. The Cochrane Library was searched using the headings 'obstructive lung disease', 'respiratory insufficiency' and 'exacerbation'. The bibliographies of the retrieved articles were examined for further references. For the evaluation of adverse effects, a limited search was undertaken to identify clinical trials and review articles that were indexed in MEDLINE, using the keywords 'steroids-adverse effects' and 'obstructive lung disease'. The search

2002 DARE.

131. Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. (Abstract)

Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. Inhaled short acting beta2 adrenergic agonists and ipratropium bromide are both used in the treatment of acute exacerbations of chronic obstructive pulmonary disease.In patients with acute exacerbations of COPD to: 1. To assess the efficacy of short-acting beta-2 agonists against placebo; 2. Compare the efficacy of short-acting beta-2 agonists and ipratropium.A comprehensive (...) in acute exacerbations of COPD and none that have compared these agents directly with placebo. None of the studies used the more modern beta2-agonists used most widely in this setting (salbutamol and terbutaline). Beta2-agonists and ipratropium both produce small improvements in FEV1, but beta2-agonists may worsen PaO2 for a period. We could not draw conclusions concerning possible additive effects.

2001 Cochrane

132. Management of acute exacerbations of chronic obstructive pulmonary disease

, and bronchodilators); however, some therapies lack evidence of efficacy (mucolytics and physical therapy). The more aggressive strategy of NPPV benefits some patients with acute exacerbation of chronic obstructive pulmonary disease and acute respiratory failure. Project page URL URL for DARE abstract Indexing Status Subject indexing assigned by CRD MeSH Adrenal Cortex Hormones; Anti-Bacterial Agents; Bronchodilator Agents; Expectorants; Lung Diseases, Obstructive; Physical Therapy (Specialty); Positive-Pressure (...) for Healthcare Research and Quality (AHRQ). Management of acute exacerbations of chronic obstructive pulmonary disease. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 19. 2001 Authors' objectives The objectives of this report are to assess the evidence currently available on the diagnosis, prognosis, and management of acute exacerbation of chronic obstructive pulmonary disease (COPD), and on the use of noninvasive positive pressure ventilation (NPPV

2001 Health Technology Assessment (HTA) Database.

133. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. (Abstract)

Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. The role of antibiotics in treatment of patients with moderate exacerbations of chronic obstructive pulmonary disease (COPD) is uncertain, but such treatment might be useful in very severe episodes. Our objective was to assess the effects of ofloxacin in patients with exacerbations of COPD who required mechanical ventilation.We did (...) a prospective, randomised, double-blind, placebo-controlled trial in 93 patients with acute exacerbation of COPD who required mechanical ventilation. Patients were randomly assigned to receive oral ofloxacin 400 mg once daily (n=47) or placebo (46) for 10 days. Primary endpoints were death in hospital and need for an additional course of antibiotics, both separately and in combination. Analysis was by intention to treat.Three patients dropped out of the study. Two (4%) patients receiving ofloxacin died

2001 Lancet Controlled trial quality: predicted high

134. Management of acute exacerbations of chronic obstructive pulmonary disease

Management of acute exacerbations of chronic obstructive pulmonary disease Management of acute exacerbations of chronic obstructive pulmonary disease Management of acute exacerbations of chronic obstructive pulmonary disease McCrory D C, Brown C, Gray R N, Goslin R E, Kolimaga J T, MacIntyre N R, Oddone E Z, Matchar D B Authors' objectives To assess the evidence currently available on the diagnosis, prognosis and management of acute exacerbation of chronic obstructive pulmonary disease (COPD (...) care. Funding Agency for Healthcare Research and Quality, contract number 290-97-0014. Bibliographic details McCrory D C, Brown C, Gray R N, Goslin R E, Kolimaga J T, MacIntyre N R, Oddone E Z, Matchar D B. Management of acute exacerbations of chronic obstructive pulmonary disease. Rockville, MD, USA: Agency for Healthcare Research and Quality. Evidence Report/Technology Assessment; 19. 2001 Original Paper URL Other publications of related interest 1. Snow V, Lascher S, Mottur-Pilson C. Evidence

2001 DARE.

135. Economic impact of using an immunostimulating agent to prevent severe acute exacerbations in patients with chronic obstructive pulmonary disease

Journal 2001; 8(1): 27-33 PubMedID Other publications of related interest Anthonisen N R. OM-85 BV for COPD. American Journal of Respiratory and Critical Care Medicine 1997;156: 1713-4. Collet J P, Shapiro S, Ernst P, Renzi T, Ducruet T, Robinson A, for the PARI-IS Study Steering Committee and Research Group. Effects of an immunostimulating agent on acute exacerbations and hospitalisations in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care (...) to increase the efficiency of the drug and to optimise the benefits. Source of funding Funded by Jouveinal Inc. Dr J-P Collet was supported by a personal research grant from the Fond de la Recherche en Sante due Quebec. Bibliographic details Collet J P, Ducruet T, Haider S, Shapiro S, Robinson A, Renzi P M, Contandriopoulos A P, Ernst P. Economic impact of using an immunostimulating agent to prevent severe acute exacerbations in patients with chronic obstructive pulmonary disease. Canadian Respiratory

2001 NHS Economic Evaluation Database.

136. Corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. (Abstract)

Corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Acute exacerbations occur quite commonly in patients with chronic obstructive pulmonary disease (COPD). Corticosteroid drugs, either parenteral or oral, are used commonly in this setting.To determine the effect of corticosteroids, administered either parenterally or orally, on the outcome in patients with acute exacerbations of COPD.An initial search was carried out using the Cochrane Airways Group COPD register (...) significant benefit for corticosteroid treatment, but the number of studies reporting these outcomes was small and there was significant heterogeneity between themTreatment with oral or parenteral corticosteroids in outpatients may decrease the number of patients requiring further treatment or hospitalisation, but otherwise it has no significant effect on the outcome of acute exacerbations of chronic obstructive airways disease. Further research is required to determine the place of corticosteroid

2000 Cochrane

137. "Hospital at home" versus hospital care in patients with exacerbations of chronic obstructive pulmonary disease: prospective randomised controlled trial. Full Text available with Trip Pro

"Hospital at home" versus hospital care in patients with exacerbations of chronic obstructive pulmonary disease: prospective randomised controlled trial. To compare "hospital at home" and hospital care as an inpatient in acute exacerbations of chronic obstructive pulmonary disease.Prospective randomised controlled trial with three months' follow up.University teaching hospital offering secondary care service to 350 000 patients.Selected patients with an exacerbation of chronic obstructive (...) care were readmitted at three months. No significant difference was found in mortality between the groups at three months (9% versus 8%).Hospital at home care is a practical alternative to emergency admission in selected patients with exacerbations of chronic obstructive pulmonary disease.

2000 BMJ Controlled trial quality: predicted high

138. What is the optimal dose of intravenous corticosteroid for initial management of acute exacerbations of asthma and COPD?

of corticosteroids on time to discharge, adverse events or quality of life. - We are unable to reach conclusions regarding the dosing effect for intravenous and oral corticosteroids individually. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Adrenal Cortex Hormones; Asthma /drug therapy; Pulmonary Disease, Chronic Obstructive /drug therapy Language Published English Country of organisation Australia Address for correspondence Monash Institute of Health Services Research, Block E, Monash (...) What is the optimal dose of intravenous corticosteroid for initial management of acute exacerbations of asthma and COPD? What is the optimal dose of intravenous corticosteroid for initial management of acute exacerbations of asthma and COPD? What is the optimal dose of intravenous corticosteroid for initial management of acute exacerbations of asthma and COPD? Hender K Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality

2000 Health Technology Assessment (HTA) Database.

139. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. (Abstract)

Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Within the intensive-care unit, non-invasive ventilation (NIV) can prevent the need for intubation and the mortality associated with severe episodes of chronic obstructive pulmonary disease (COPD). The aim of this study was to find whether the introduction of NIV, early after the admission on a general respiratory ward (...) improvement in pH in the first hour (p=0.02) and a greater fall in respiratory rate at 4 h (p=0.035). The duration of breathlessness was also reduced by NIV (p=0.025).The early use of NIV for mildly and moderately acidotic patients with COPD in the general ward setting leads to more rapid improvement of physiological variables, a reduction in the need for invasive mechanical ventilation (with objective criteria), and a reduction in in-hospital mortality.

2000 Lancet Controlled trial quality: uncertain

140. Eficacia de los glucocorticoides en las reagudizaciones de la enfermedad pulmonar obstructiva cronica: metaanalisis de los estudios publicados [The efficacy of corticosteroids in exacerbations of chronic obstructive pulmonary disease: meta-analysis of pub

-analysis of published studies] Eficacia de los glucocorticoides en las reagudizaciones de la enfermedad pulmonar obstructiva cronica: metaanalisis de los estudios publicados [The efficacy of corticosteroids in exacerbations of chronic obstructive pulmonary disease: meta-analysis of published studies] Riancho J A, Portero I, Cubian I Authors' objectives To evaluate the efficacy of corticosteroids for exacerbations of chronic obstructive pulmonary disease (COPD). Searching MEDLINE (from 1966 to 1999 (...) Eficacia de los glucocorticoides en las reagudizaciones de la enfermedad pulmonar obstructiva cronica: metaanalisis de los estudios publicados [The efficacy of corticosteroids in exacerbations of chronic obstructive pulmonary disease: meta-analysis of pub Eficacia de los glucocorticoides en las reagudizaciones de la enfermedad pulmonar obstructiva cronica: metaanalisis de los estudios publicados [The efficacy of corticosteroids in exacerbations of chronic obstructive pulmonary disease: meta

2000 DARE.